ALLR
Allarity Therapeutics, Inc.1.0700
+0.0100+0.94%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
16.91MP/E (TTM)
0.12Basic EPS (TTM)
9.11Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
FDA Fast Track for stenoparib
Allarity Therapeutics announced on August 26, 2025, that the FDA granted Fast Track designation to stenoparib, its dual PARP and WNT inhibitor, for advanced ovarian cancer patients. This speeds up development and review, addressing unmet needs through more FDA interactions and potential accelerated approval. The ongoing Phase 2 trial, with first patient dosed in early June 2025, uses DRP companion diagnostics to select responders, building on prior data showing benefits lasting over 22 months. Fast Track boosts momentum, yet clinical uncertainties linger.
10-Q
Q2 FY2025 results
Allarity Therapeutics narrowed its Q2 operating loss to $4.1 million, up 23% year-over-year from $3.4 million, driven by a 119% jump in research and development spending to $2.3 million for stenoparib's Phase II trial expansion in advanced ovarian cancer, while general and administrative costs dropped 22% to $1.8 million. Net loss improved to $2.3 million from $1.6 million, aided by $1.6 million in foreign exchange gains offsetting prior warrant fair-value boosts. Cash stood at $17.8 million after $9.7 million from ATM stock sales and a $2.6 million share repurchase, with operating cash use at $8.2 million for the half-year. Stenoparib advances steadily. Yet regulatory hurdles loom large.
8-K
New DRP® licensing deal signed
Allarity Therapeutics signed a commercial agreement on July 15, 2025, granting a non-exclusive global license to selected proprietary DRP® algorithms for breast cancer to an undisclosed EU-based biotech firm, plus laboratory services from its Danish facility. The deal includes one-year purchase commitments for transcriptome analysis to aid precision oncology, validating the platform's broad use while offsetting costs. It won't materially affect financials. Forward-looking plans hinge on partnership expansion amid clinical and regulatory risks.
ALLO
Allogene Therapeutics, Inc.
1.54+0.07
ALXO
ALX Oncology Holdings Inc.
1.43+0.03
APLM
Apollomics Inc.
17.02+0.92
APRE
Aprea Therapeutics, Inc.
0.91-0.01
MNPR
Monopar Therapeutics Inc.
71.47-3.65
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
RLAY
Relay Therapeutics, Inc.
8.48+0.00
RPTX
Repare Therapeutics Inc.
2.23+0.03
TCRT
Alaunos Therapeutics, Inc.
4.36+0.09